3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
9
Cetuximab
5
Surveys and Questionnaires
4
Cisplatin
4
dostarlimab
2
abemaciclib
2
Standard of Care
2
Docetaxel
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
ulixertinib
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
tipifarnib
1
ribociclib
1
repotrectinib
1
patritumab deruxtecan
1
palbociclib
1
olaparib
1
nimotuzumab
1
monalizumab
1
ibrutinib
1
fludarabine
1
exemestane
1
entrectinib
1
ebselen
1
durvalumab
1
disitamab vedotin
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Radionuclide Imaging
×
30 days
×
Clear all
NCT06904365
2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
10 enrolled